LGApr 25

TEMPO: Transformers for Temporal Disease Progression from Cross-Sectional Data

arXiv:2604.2336816.3h-index: 1
AI Analysis

For researchers modeling disease progression from cross-sectional data, TEMPO provides a more accurate and flexible alternative to Event-Based Models, eliminating the need for custom inference algorithms.

TEMPO is a Transformer-based model that learns both ordinal and continuous event sequences from cross-sectional data for disease progression modeling. It reduces normalized Kendall's Tau distance by 52.89% and staging MAE by 25.33% over state-of-the-art SA-EBM on synthetic benchmarks, and recovers a biologically plausible Alzheimer's progression on ADNI data.

Event-Based Models (EBMs) infer biomarker progression from cross-sectional data but typically only as ordinal sequences and rely on rigid model assumptions. We propose \textsc{Tempo}, a Transformer architecture that learns both ordinal and continuous event sequences through simulation-based supervised learning. \textsc{Tempo} uses two Transformer modules: one treats biomarkers as tokens to infer event sequencing; the other treats patients as tokens, representing each by their per-biomarker abnormality profile, to infer patients' disease stages. On synthetic benchmarks, \textsc{Tempo} reduces normalized Kendall's Tau distance by 52.89\% and staging MAE by 25.33\% compared to state-of-the-art SA-EBM, with larger reductions in high-dimensional settings (58.88\% and 61.10\%). Applied to ADNI, \textsc{Tempo} recovers a biologically plausible Alzheimer's progression: early medial temporal atrophy, followed by amyloid accumulation and cognitive decline, and late-stage tau pathology with terminal acceleration of global neurodegeneration -- broadly consistent with established disease models. \textsc{Tempo} also eliminates the need to derive custom inference algorithms and enables rapid empirical comparison of generative hypotheses.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes